Masseundersøkelsen mot livmorhalskreft - Oslo universitetssykehus

More documents

Recommendations

Info

EFFICACY OF CANCER SCREENING ON CAUSE-SPECIFIC INCIDENCE-BASED MORTALITY Site, test Cervix F, Pap smear Breast F, Mammography Colorectum MF, FOBT Target age, scr interval 25 or 30 to 64, 3-5 y 50 to 69, 2 y 50 to 74, 2 y Mortality outcome among invited Reference ≥80% IARC 2005 WHO 2006 25% IARC 2002 SOSSEG 2006 16% Hewitson et al. 2007
Percentage reduction in the cumulative rate of invasive Sq Cx Ca over the age range 35-64 years, with different frequencies of screening (IARC 1986) Screening frequency % reduction in the cumulative rate 1 year 93.5 31-44 3 years 90.8 12-15 5 years 83.6 7-8 10 years 64.1 4 Number of tests Assuming a negative screen occurring at age 35 years, and that a previous negative screen had been performed
Page 1 and 2: Masseundersøkelsen mot livmorhalsk
Page 4 and 5: 26/10/2012
Page 6 and 7: Livmorhalskreft, patogenese > Oppst
Page 8 and 9: Forekomst > Den vanligste seksuelt
Page 10 and 11: Kriterier for screening > Sykdomsfo
Page 14 and 15: Det naturlige sykedomsforløpet > U
Page 16 and 17: Fordeler og ulemper ved screening >
Page 18 and 19: Litt historikk > «Pap-smear» (195
Page 20 and 21: Organisering > Masseundersøkelsen
Page 22 and 23: Masseundersøkelsen mot livmorhalsk
Page 24 and 25: Utredning av uavklart eller positiv
Page 26 and 27: Algoritme Normal celleprøve Uklar
Page 28 and 29: Sekundærscreening med HPV-tester >
Page 30 and 31: 80% 70% 60% 50% 40% 30% 20% 10% 0%
Page 32 and 33: 68% 66% 64% 62% 60% 58% 56% 54% 52%
Page 34 and 35: Anbefalinger: Teori og praksis > Ev
Page 36 and 37: Celleprøver - cytologiske resultat
Page 38 and 39: Vaksine > Siden 2009 har jenter i a
Page 40 and 41: Utfordringer for masseundersøkelse
Page 42 and 43: Fremtidens screeningprogram > Ny Kr
Page 44: Takk for oppmerksamheten Mer inform

Masseundersøkelsen mot livmorhalskreft - Oslo universitetssykehus

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?